Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
Faı̈ez Zannad, Christopher P. Cannon, William C. Cushman, et al.
The Lancet (2015) Vol. 385, Iss. 9982, pp. 2067-2076
Closed Access | Times Cited: 716

Showing 1-25 of 716 citing articles:

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski, Adriaan A. Voors, Stefan D. Anker, et al.
European Heart Journal (2016) Vol. 37, Iss. 27, pp. 2129-2200
Open Access | Times Cited: 19159
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
European Heart Journal (2021) Vol. 42, Iss. 36, pp. 3599-3726
Open Access | Times Cited: 8765
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Circulation (2022) Vol. 145, Iss. 18
Open Access | Times Cited: 3031
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Jennifer B. Green, M. Angelyn Bethel, Paul W. Armstrong, et al.
New England Journal of Medicine (2015) Vol. 373, Iss. 3, pp. 232-242
Open Access | Times Cited: 2326
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 17, pp. e263-e421
Open Access | Times Cited: 1516
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa McDonagh, Marco Metra, Marianna Adamo, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 1, pp. 4-131
Open Access | Times Cited: 1508
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, et al.
JAMA (2018) Vol. 321, Iss. 1, pp. 69-69
Open Access | Times Cited: 962
Clinical Update: Cardiovascular Disease in Diabetes Mellitus
Cecilia C. Low Wang, Connie N. Hess, William R. Hiatt, et al.
Circulation (2016) Vol. 133, Iss. 24, pp. 2459-2502
Open Access | Times Cited: 951
Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association
Janani Rangaswami, Vivek Bhalla, John E. Blair, et al.
Circulation (2019) Vol. 139, Iss. 16
Open Access | Times Cited: 910
Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY
Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, et al.
Endocrine Practice (2016) Vol. 22, Iss. 1, pp. 84-113
Open Access | Times Cited: 692
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Nikolaus Marx, Massimo Federici, Katharina Schütt, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4043-4140
Open Access | Times Cited: 680
2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure
Justin A. Ezekowitz, Eileen O’Meara, Michael McDonald, et al.
Canadian Journal of Cardiology (2017) Vol. 33, Iss. 11, pp. 1342-1433
Open Access | Times Cited: 622
Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes
Nisa M. Maruthur, Eva Tseng, Susan Hutfless, et al.
Annals of Internal Medicine (2016) Vol. 164, Iss. 11, pp. 740-740
Closed Access | Times Cited: 598
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
Petar Seferović, Mark C. Petrie, Gerasimos Filippatos, et al.
European Journal of Heart Failure (2018) Vol. 20, Iss. 5, pp. 853-872
Open Access | Times Cited: 592
Update on the treatment of type 2 diabetes mellitus
Juan José Marín-Peñalver, Iciar Martín-Timón, Cristina Sevillano-Collantes, et al.
World Journal of Diabetes (2016) Vol. 7, Iss. 17, pp. 354-354
Open Access | Times Cited: 568
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary
Alan J. Garber, Yehuda Handelsman, George Grunberger, et al.
Endocrine Practice (2020) Vol. 26, Iss. 1, pp. 107-139
Open Access | Times Cited: 547
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
Kenneth B. Margulies, Adrian F. Hernandez, Margaret M. Redfield, et al.
JAMA (2016) Vol. 316, Iss. 5, pp. 500-500
Open Access | Times Cited: 536
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck, Juris J. Meier, Matthew A. Cavender, et al.
Circulation (2017) Vol. 136, Iss. 9, pp. 849-870
Open Access | Times Cited: 498
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, et al.
Endocrine Practice (2018) Vol. 24, Iss. 1, pp. 91-121
Closed Access | Times Cited: 491
9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018

Diabetes Care (2017) Vol. 41, Iss. Supplement_1, pp. S86-S104
Open Access | Times Cited: 465
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020

Diabetes Care (2019) Vol. 43, Iss. Supplement_1, pp. S111-S134
Open Access | Times Cited: 446
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019

Diabetes Care (2018) Vol. 42, Iss. Supplement_1, pp. S103-S123
Open Access | Times Cited: 417
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021

Diabetes Care (2020) Vol. 44, Iss. Supplement_1, pp. S125-S150
Closed Access | Times Cited: 399
A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 5, pp. 665-675
Open Access | Times Cited: 373
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein, et al.
Diabetes Care (2017) Vol. 41, Iss. 1, pp. 14-31
Open Access | Times Cited: 350
Page 1 - Next Page

Scroll to top